Are You Taking One of These 10 Drugs Medicare Is Discounting in 2026?
Millions of Americans rely on Medicare to help cover the cost of their prescription medications. In a historic move, Medicare will begin negotiating prices for some of the most widely used and expensive drugs starting in 2026. If you or a loved one takes one of these medications, you could see significant savings.
Understanding Medicare Drug Price Negotiations
For the first time, the federal government has been granted the authority to negotiate prices directly with drug manufacturers for certain high-cost medications covered under Medicare Part D. This change is part of the Inflation Reduction Act, aiming to make prescription drugs more affordable for seniors and people with disabilities. The initial list of 10 drugs was selected based on their high spending and widespread use among Medicare beneficiaries.
The 10 Drugs Selected for Medicare Price Negotiation
- Eliquis (apixaban) – Blood thinner for preventing blood clots and stroke
- Xarelto (rivaroxaban) – Another blood thinner for similar uses
- Jardiance (empagliflozin) – Used to treat type 2 diabetes and heart failure
- Januvia (sitagliptin) – Type 2 diabetes medication
- Farxiga (dapagliflozin) – Treats type 2 diabetes, heart failure, and chronic kidney disease
- Entresto (sacubitril/valsartan) – Heart failure medication
- Enbrel (etanercept) – Used for rheumatoid arthritis and other autoimmune conditions
- Imbruvica (ibrutinib) – Treats certain blood cancers
- Stelara (ustekinumab) – Used for psoriasis, Crohn's disease, and ulcerative colitis
- Fiasp/NovoLog (insulin aspart) – Fast-acting insulin for diabetes
Why These Drugs Were Chosen
The selected drugs represent some of the highest Medicare Part D spending, accounting for billions of dollars in annual costs. They are commonly prescribed for chronic conditions such as diabetes, heart disease, autoimmune disorders, and cancer. By targeting these medications, Medicare aims to provide relief to the largest number of beneficiaries and make a meaningful impact on out-of-pocket costs.
What This Means for Medicare Beneficiaries
If you take one of these medications, you could see lower copays and reduced out-of-pocket expenses starting in 2026. The exact savings will depend on the outcome of the negotiations and your specific Medicare plan. However, experts anticipate that the changes will help millions of seniors better afford their essential medications and reduce the financial burden of managing chronic health conditions.
How to Prepare for the Changes
Medicare beneficiaries should stay informed about updates to their prescription drug coverage. Review your plan’s formulary each year during open enrollment, and talk to your healthcare provider or pharmacist about how these changes may affect your medication costs. If you’re not sure whether you take one of the drugs on the list, check your prescription labels or consult your doctor.
The Future of Medicare Drug Price Negotiations
The 2026 rollout is just the beginning. Medicare plans to expand negotiations to include more drugs in the coming years, potentially increasing savings for even more beneficiaries. This initiative marks a significant shift in how prescription drug prices are set in the United States and could pave the way for broader reforms in the future.
Final Thoughts
The upcoming Medicare drug price negotiations represent a major step toward making prescription medications more affordable for millions of Americans. If you take one of the 10 targeted drugs, keep an eye out for updates from Medicare and your plan provider. Lower drug costs could be just around the corner, helping you stay healthy without breaking the bank.